AR065272A1 - Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas - Google Patents

Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas

Info

Publication number
AR065272A1
AR065272A1 ARP080100555A ARP080100555A AR065272A1 AR 065272 A1 AR065272 A1 AR 065272A1 AR P080100555 A ARP080100555 A AR P080100555A AR P080100555 A ARP080100555 A AR P080100555A AR 065272 A1 AR065272 A1 AR 065272A1
Authority
AR
Argentina
Prior art keywords
compound
thiazolidinodiona
same
manufacturing methods
crystal forms
Prior art date
Application number
ARP080100555A
Other languages
English (en)
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of AR065272A1 publication Critical patent/AR065272A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Una forma cristalina en base a un compuesto de tiazolidinodiona, que es efectivo como un ingrediente farmacéutico para fabricar un activador del receptor activado por el multiplicador de peroxisomas (PPAR)gamma, una composicion farmacéutica contra el cáncer; y un método de preparacion de la forma cristalina. La presente se refiere a una forma cristalina de un hidrato de diclorhidrato de 5-(4-{[6-(4-amino-3,5-dimetilfenoxi)-1-metil-1-H-bencimidazol-2-il]metoxi}bencil)-1,3-tiazolidino-2,4- diona, representado por la formula (1).
ARP080100555A 2007-02-08 2008-02-08 Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas AR065272A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90025107P 2007-02-08 2007-02-08

Publications (1)

Publication Number Publication Date
AR065272A1 true AR065272A1 (es) 2009-05-27

Family

ID=39521789

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100555A AR065272A1 (es) 2007-02-08 2008-02-08 Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas

Country Status (18)

Country Link
US (2) US8236834B2 (es)
EP (1) EP2086971A1 (es)
JP (1) JP5748954B2 (es)
KR (1) KR20090107013A (es)
CN (1) CN101578283B (es)
AR (1) AR065272A1 (es)
AU (1) AU2008215384B2 (es)
BR (1) BRPI0805830A2 (es)
CA (2) CA2728541C (es)
IL (1) IL197825A0 (es)
MX (1) MX2009003535A (es)
NZ (1) NZ575786A (es)
PE (1) PE20090647A1 (es)
RU (1) RU2414470C2 (es)
SG (1) SG193039A1 (es)
TW (2) TW201336497A (es)
WO (1) WO2008099944A1 (es)
ZA (1) ZA200902354B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
JPWO2010013769A1 (ja) * 2008-07-31 2012-01-12 第一三共株式会社 チアゾリジンジオン化合物の結晶及びその製造方法
EP2305673A4 (en) * 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
US8420819B2 (en) * 2009-06-03 2013-04-16 Boehringer Ingelheim International Gmbh Process for optimizing the particle size of an active pharmaceutical ingredient by crystallization
WO2011065420A1 (ja) 2009-11-26 2011-06-03 第一三共株式会社 ６－置換－１－メチル－１ｈ－ベンズイミダゾール誘導体の製造法及びその製造中間体
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013068486A1 (en) 2011-11-08 2013-05-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of male infertility
JP6800013B2 (ja) 2013-03-14 2020-12-16 ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ 重水素化２，４−チアゾリジンジオン及び治療方法
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3488099B2 (ja) * 1997-10-08 2004-01-19 三共株式会社 置換縮合複素環化合物
ES2221203T3 (es) * 1997-10-08 2004-12-16 Sankyo Company Limited Compuesto heterociclico fusionado sustituido.
TR200103183T2 (tr) 1999-04-07 2002-05-21 Sankyo Company Limited Amin türevi bileşimler
JP4169450B2 (ja) * 1999-04-07 2008-10-22 第一三共株式会社 インスリン抵抗性改善剤
EP1175418A2 (en) * 1999-04-23 2002-01-30 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic
YU80302A (sh) 2000-04-25 2005-11-28 Kyorin Pharmaceutical Co. Ltd. Novi stabilni kristal derivata tiazolidinediona i postupak za proizvodnju istog
TW200300677A (en) * 2001-12-11 2003-06-16 Sankyo Co A pharmaceutical composition
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
JP2004083574A (ja) 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
AU2003246187A1 (en) * 2002-06-25 2004-01-06 Sankyo Company, Limited MEDICINAL COMPOSITION CONTAINING DIURETIC AND PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) Gamma ACTIAVTOR
JP2004075448A (ja) 2002-08-15 2004-03-11 Taiyo Yuden Co Ltd 圧電磁器組成物、圧電磁器組成物の製造方法および圧電セラミック部品
JP2005162727A (ja) * 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP4789180B2 (ja) * 2004-09-28 2011-10-12 第一三共株式会社 ６−置換−１−メチル−１−ｈ−ベンズイミダゾール誘導体の製造方法及びその製造中間体
CN102391203A (zh) 2004-09-28 2012-03-28 三共株式会社 制备6-取代的-1-甲基-1-h-苯并咪唑衍生物的方法及其合成中间体
JP5133071B2 (ja) 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
EP2305673A4 (en) 2008-07-31 2011-11-02 Daiichi Sankyo Co Ltd CRYSTAL OF A THIAZOLIDINE CONNECTION AND METHOD FOR THE PRODUCTION THEREOF
JPWO2010013769A1 (ja) 2008-07-31 2012-01-12 第一三共株式会社 チアゾリジンジオン化合物の結晶及びその製造方法

Also Published As

Publication number Publication date
JP2010517932A (ja) 2010-05-27
KR20090107013A (ko) 2009-10-12
WO2008099944A1 (en) 2008-08-21
AU2008215384A8 (en) 2009-06-11
TW200838512A (en) 2008-10-01
CA2665048C (en) 2011-11-08
US20110213158A9 (en) 2011-09-01
AU2008215384B2 (en) 2011-06-23
US8552038B2 (en) 2013-10-08
US8236834B2 (en) 2012-08-07
SG193039A1 (en) 2013-09-30
ZA200902354B (en) 2010-03-31
IL197825A0 (en) 2009-12-24
CA2665048A1 (en) 2008-08-21
CA2728541A1 (en) 2008-08-21
US20120252854A1 (en) 2012-10-04
JP5748954B2 (ja) 2015-07-15
AU2008215384A1 (en) 2008-08-21
CN101578283A (zh) 2009-11-11
EP2086971A1 (en) 2009-08-12
NZ575786A (en) 2011-05-27
BRPI0805830A2 (pt) 2011-08-30
MX2009003535A (es) 2009-05-11
CN101578283B (zh) 2013-01-02
TW201336497A (zh) 2013-09-16
RU2009115179A (ru) 2010-10-27
RU2414470C2 (ru) 2011-03-20
PE20090647A1 (es) 2009-05-29
US20110046388A1 (en) 2011-02-24
CA2728541C (en) 2013-04-02

Similar Documents

Publication Publication Date Title
AR065272A1 (es) Formas cristalinas de un compuesto de tiazolidinodiona, y metodos de fabricacion de las mismas
PE20120002A1 (es) Derivados de benceno sustituido con glucopiranosilo como inhibidores de sglt2
UY31244A1 (es) Profarmacos dipeptoides y su uso
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
NI201000107A (es) Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa.
PE20140171A1 (es) Pirazoles fungicidas y sus mezclas
UY29766A1 (es) Formas cristalinas delta y épsilon de mesilato de imatinib
AR067090A1 (es) Espiriciclos como inhibidores de la 11- beta hidroxiesteroide deshidrogenasa de tipo 1
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
PE20120812A1 (es) Compuestos vinil indazolilo
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
CR20120277A (es) Una forma cristalina y amorfa de genz 112638 hemitartrato como inhibidores de glucosilceramida sintasa
PT2178881E (pt) Novos derivados de 6-triazolopiridazina-sulfanil benzotiazole e benzimidazole, seu método de preparação, sua aplicação como medicamentos, composições farmacêuticas e nova utilização como inibidores de met
MX2010006893A (es) Derivados de benzotiazol y benzoxazol y metodos de uso.
AR068187A1 (es) Forma cristalina de un intermediario sintetico para la preparacion de un inhibidor de dpp-iv
CO6300946A2 (es) Forma cristalina de derivado de fenilamino pirimidina
WO2009021868A3 (en) Novel piperazine amide derivatives
CL2009000004A1 (es) Forma cristalina de r-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida; composicion farmaceutica que comprende a dicha forma cristalina; y uso para el tratamiento de diabetes o hiperglicemia.
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
UY31527A1 (es) Derivados ciclopropilamina
PE20090798A1 (es) Derivados de benzotiazol como moduladores del receptor de grelina
CO2023006521A2 (es) Forma cristalina iv del compuesto agonista de receptor de melanocortina y método de preparación para la misma
AR083100A1 (es) Monohidrato de derivados de aza-adamantano
SI1891952T1 (sl) Farmacevtski sestavek, ki vsebuje olmesartan medoksomil
CO2023006515A2 (es) Forma cristalina i del compuesto agonista de receptor de melanocortina y método de preparación para la misma

Legal Events

Date Code Title Description
FA Abandonment or withdrawal